MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
36.20
-0.17
-0.47%
Pre Market: 36.35 +0.15 +0.41% 09:12 05/14 EDT
OPEN
36.57
PREV CLOSE
36.37
HIGH
37.32
LOW
34.90
VOLUME
13.88K
TURNOVER
0
52 WEEK HIGH
173.25
52 WEEK LOW
34.90
MARKET CAP
3.56B
P/E (TTM)
-12.6040
1D
5D
1M
3M
1Y
5Y
1D
Sarepta Therapeutics' Elevidys Gets Approval In Japan To Treat Duchenne Muscular Dystrophy
NASDAQ · 21h ago
Sarepta announces Japan approval for Elevidys
TipRanks · 23h ago
SAREPTA THERAPEUTICS INC: ELIGIBLE TO RECEIVE UP TO $103.5M IN NEAR-TERM REGULATORY & COMMERCIAL MILESTONE PAYMENTS
Reuters · 23h ago
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
Barchart · 1d ago
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
The Motley Fool · 1d ago
Weekly Report: what happened at SRPT last week (0505-0509)?
Weekly Report · 2d ago
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets
Benzinga · 4d ago
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
Benzinga · 5d ago
More
About SRPT
More
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Recently
Symbol
Price
%Change

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.